Objectives: A new, pharmacokinetically enhanced, oral formulation of amoxicillin/ clavulanic acid has been developed to overcome resistance in the major bacterial respiratory pathogen Streptococcus pneumoniae, while maintaining excellent activity against Haemophilus influenzae and Moraxella catarrhalis, including beta-lactamase producing strains. This study was conducted to provide in vitro susceptibility data for amoxicillin/clavulanic acid and 16 comparator agents against the key respiratory tract pathogens. Methods: Susceptibility testing was performed on 9172 isolates collected from 95 centers in North America, Europe, Australia, and Hong Kong by broth microdilution MIC determination, according to NCCLS methods, using amoxicillin/clavulanic acid and 16 comparator antimicrobial agents. Results were interpreted according to NCCLS breakpoints and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints based on oral dosing regimens.
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Introduction
According to the World Health Organization Global Burden of Disease assessment, lower respiratory infections are the fourth highest cause of mortality in developed regions, accounting for 324,000 or 3.5% of all deaths in 1990, and the leading cause of mortality in developing regions, accounting for 3,915,000 or 9.9% of all deaths. 1 The 1999 WHO estimate of worldwide deaths due to all respiratory infections was 4,039,000, with the majority again being in the developing world. Recent data from the USA identify acute respiratory infection as the seventh highest cause of death, with 62,034 deaths attributed to pneumonia in 2001. 2 The most commonly reported bacterial pathogen in acute respiratory infections is consistently Streptococcus pneumoniae [3] [4] [5] found in 20-60% of patients with community-acquired pneumonia (CAP) and 20-43% of patients with acute sinusitis. 6 In a recent meta-analysis of CAP in 33,148 patients in 127 studies, 86% of deaths (1019 of 1187) among patients with identifiable pathogens were in patients with Streptococcus pneumoniae infections. 7 Haemophilus influenzae is the most common cause of acute exacerbations of chronic bronchitis (AECB) 8 and is also identified in 3-10% of CAP. Other, less common though nonetheless serious contributors to respiratory disease include Moraxella catarrhalis (1-2%) and Legionella pneumophila (1-6%). 9, 10 Streptococcus pyogenes, the most frequent cause of severe pharyngitis and exudative tonsillitis, and an occasional cause of severe invasive infections, contributes significant morbidity in both adults and children. Rheumatic fever, a complication of S. pyogenes infection, is infrequent in the developed world, but is still a significant problem in the developing world, occurring most frequently in the age group 3-15 years. 10 Several drugs have shown excellent activity against antimicrobial-resistant S. pneumoniae, including amoxicillin, amoxicillin/clavulanic acid, and the newer fluoroquinolones. 11, 12 While fluoroquinolones are an important part of the antimicrobial armamentarium, their overuse has resulted in the development and spread of resistance to these agents in many species such as staphylococci and Enterobacteriaceae. Amoxicillin/clavulanic acid was developed to enhance the activity of amoxicillin against b-lactamase-producing bacteria, by the addition of the b-lactamase inhibitor, clavulanic acid. This agent has been used for more than 15 years as an oral antimicrobial agent and has maintained in vitro activity against the major respiratory tract pathogens. A new formulation of amoxicillin/ clavulanic acid has recently been developed with an enhanced pharmacokinetic profile which extends the time the plasma drug concentration exceeds the MICs of pathogens (T > MIC) in the serum. Each tablet consists of a layer of immediate-release amoxicillin trihydrate plus clavulanic acid and a layer of sustained-release amoxicillin sodium. It has been shown that, for beta-lactams, a plasma T > MIC for !40% of the dosing interval correlates with high rates of bacteriological cure. 13 Pharmacokinetically-enhanced amoxicillin/clavulanic acid provides plasma amoxicillin levels above 4 mg/mL (amoxicillin component) for 49% of the dosing interval, and therefore should be able to eradicate pathogens, including many penicillin-resistant strains, with MICs of 4 mg/mL (amoxicillin component). empirically, with adjustments to treatment based both on clinical response and as specific laboratory data become available. 15 For this reason it is important for the clinician to know the local prevalence of resistance so that empiric choices of antibiotics can be made rationally.
This study was conducted to provide in vitro susceptibility data for amoxicillin/clavulanic acid and 17 comparator agents against the key respiratory tract pathogens, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes.
Methods and materials
Isolates were collected from 89 centers within the USA, Australia, Canada, Hong Kong, Mexico, Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden, and the United Kingdom. Most centers were large hospitals located in major cities within each country.
Strains included in the study were isolated from cultures of blood, sputum, bronchoalveolar lavage (BAL), middle ear fluid, nasopharyngeal swabs or aspirates, paranasal sinuses, and throat specimens (Streptococcus pyogenes only) between May 1999 and December 2000. Patients from whom isolates were recovered had been diagnosed with community-acquired respiratory tract infections (RTI) and were outpatients or hospitalized patients within 48 hours of admission. All RTI isolates were submitted as they were recovered (i.e. not a sampling of only certain strains). Isolates recovered from patients with nosocomially-acquired infections, or cystic fibrosis disease were excluded from the study.
Isolates from patients of all ages were accepted. Isolates were submitted to two testing sites for centralized testing, and the identification of each isolate was confirmed following standard procedures. 16 Susceptibility testing was conducted by broth microdilution MIC determination, according to NCCLS recommended procedures, 17 using custom dried microdilution trays (TREK, Westlake, OH). All testing was carried out at Laboratory Specialists Inc., Westlake, OH or Case Western Reserve University, Cleveland, OH, except for UK strains, which were tested at GR Micro Ltd., London.
The following antimicrobial agents were tested: amoxicillin/clavulanic acid (2:1 ratio), ampicillin, amoxicillin, azithromycin, cefaclor, cefixime, cefprozil, ceftriaxone, cefuroxime axetil, ciprofloxacin, clarithromycin, clindamycin, doxycycline, erythromycin, levofloxacin, penicillin and trimethoprim/sulfamethoxazole (1:19 ratio). The microdilution trays were reconstituted with isolates suspended in Haemophilus Test Medium (HTM) broth (PML, Tualatin, OR) (H. influenzae), cation-adjusted Mueller Hinton broth supplemented with 3% lysed horse blood (CAMHB-LHB) (MicroScan, Sacramento, CA) (S. pneumoniae and S. pyogenes), or cationadjusted Mueller Hinton broth (CAMHB) (MicroScan) (M. catarrhalis). For each isolate, a suspension equivalent to a 0.5 McFarland Standard was prepared in saline and aliquots added to the broth. Viable counts were made by the laboratories at the commencement of the study to determine the volume of the 0.5 McFarland organism suspension to be added to the broth to produce an inoculum size of 3-7 Â 10 5 cfu/ml for each species. In addition, inoculum counts were determined for each isolate during testing to assure that the inocula were within the acceptable range. Trays were inoculated using an autoinoculator (TREK) to deliver 100 ml/well, incubated under ambient conditions at 35 8C for 20-24 hours, and the lowest concentration showing no growth read as the MIC.
Quality-control organisms specified by NCCLS, including S. pneumoniae ATCC 49619, H. influenzae ATCC strains 49247 and 49766, S. aureus ATCC 29213 and E. coli ATCC strains 25922 and 35218 were tested on each day of testing. In addition to the NCCLS recommended strains, a set of 50 isolates each of S. pneumoniae and H. influenzae from frozen stocks which represented a wide range of resistance profiles were used to test each new lot of dried microdilution trays. This testing showed that the trays of all lots used provided reproducible results.
Data analysis
MIC 50 's, MIC 90 's, and the proportion of isolates of each species that were susceptible were determined for the agents tested, based on NCCLS 18 and/or pharmacokinetic/pharmacodynamic (PK/ PD) interpretive criteria. PK/PD breakpoints were based on standard dosing regimens and criteria appropriate to each agent for respiratory tract infections. 13, [19] [20] [21] [22] [23] [24] [25] [26] For b-lactams, erythromycin and clarithromycin, these breakpoints were based on free drug concentrations in serum present for 40-50% of the dosing interval, while for azithromycin, the fluoroquinolones, and doxycycline, they were based on 24-hour unbound serum AUC/MIC ratio of 25 to 30 (Tables 1 and 2 ). Based on these criteria, a susceptible breakpoint of 4/2 mg/mL was used to represent the pharmacokinetically enhanced formulation of amoxicillin/clavulanic acid for all species tested. . Values shown are susceptible breakpoints in mg/mL. Isolates with MICs above the breakpoints shown were regarded as resistant.
b Amoxicillin/clavulanic acid is expressed in terms of amoxicillin. Susceptibility interpretations based on the new amoxicillin/clavulanic acid 2000/125 mg PK/PD breakpoints of 4S/8I/ !16R.
c S. pneumoniae susceptibility of cefixime is based on susceptibility to penicillin. d Breakpoints used for non-meningeal infections; breakpoints for meningitis are S, 0.5 mg/mL; I1 mg/mL, R > 2 mg/mL. e Breakpoints used for cefuroxime axetil, breakpoints for cefuroxime sodium are S 0.5 mg/mL, I1 mg/mL, R > 2 mg/mL. f Trimethoprim/sulfamethoxazole is expressed in terms of trimethoprim.
Results
There were a total of 3714 S. The prevalence of resistance in S. pneumoniae to selected agents and of b-lactamase production and trimethoprim/sulfamethoxazole resistance in H. influenzae, varied around the world (Table 3 and Figure 1 ). Five countries (France, Hong Kong, Mexico, Spain and the USA) had a prevalence of penicillin-resistant S. pneumoniae of >20%, while the Netherlands, Sweden, the UK and Germany had the lowest prevalences, at less than 5%. The highest prevalences (greater than 29%) of b-lactamase production by H. influenzae were in France, Hong Kong and the USA. The countries with the lowest prevalence (less than 5%) were Italy, the Netherlands, and Germany. The percentage of b-lactamase-negative, ampicillin-resistant (BLNAR) H. influenzae strains was 0.18%. Of the seven BLNAR isolates found in this study, five were recovered in Italy. Spain and Mexico had the highest prevalence of trimethoprim/ sulfamethoxazole-resistant H. influenzae (>30%).
Amoxicillin/clavulanic acid susceptibility rates for S. pneumoniae, based on the NCCLS breakpoint for the current amoxicillin/clavulanic acid formulation, differed among countries from >99% susceptible in the Netherlands, Germany, Sweden, and the United Kingdom, to lows of 81.4% in Hong Kong, 81.7% in Spain, and 85.3% in the USA. All other countries were over 92% (Table 3) . At the PK/PD breakpoint of 4 mg/mL (amoxicillin component) for the extended release amoxicillin/clavulanic acid formulation, >97.6% of isolates were susceptible in all countries except for Spain (93.8%) and the USA (90.4%). Thirty-seven isolates of S. pneumoniae had levofloxacin MICs of !4 mg/mL; the highest percentage of these were from Hong Kong, where 10.8% of isolates had MICs >8 mg/mL for levofloxacin. Worldwide, the prevalence of levofloxacin resistance was 0.75%, with three countries (Australia, Italy, and Sweden) having 0% and six countries (Belgium, France, Germany, the Netherlands, Spain and the United Kingdom) with prevalences of below 1%. Among these 37 resistant strains, many remained susceptible to several other agents including penicillin, clindamycin, and erythromycin. Hong Kong was the exception, with ten of 11 strains resistant to penicillin, four of 11 resistant to clindamycin, and ten of 11 levofloxacin-resistant strains being resistant to erythromycin.
In vitro activity against S. pneumoniae, based on the proportion of isolates susceptible (according to current NCCLS breakpoints and PK/PD breakpoints for agents without NCCLS breakpoints), from most active to least active, was: levofloxacin, amoxicillin/clavulanic acid (enhanced formulation), ceftriaxone, amoxicillin/clavulanic acid (current formulation), and amoxicillin, all with activity greater than 90%. Clindamycin, cefprozil, cefuroxime axetil, doxycycline, azithromycin, clarithromycin, erythromycin, cefixime, trimethoprim/ sulfamethoxazole, all showed activity from 85% to 68%, while cefaclor was at 47.8% (Table 1) .
When S. pneumoniae was classified by penicillin susceptibility category, cross-resistance with macrolides, azithromycin, doxycycline, and trimethoprim/sulfamethoxazole was noted (Table 5) .
For other b-lactam agents (except cefaclor), >98% of penicillin-susceptible isolates were susceptible, while 64% were susceptible to cefaclor at the NCCLS breakpoint. b-Lactam susceptibility of penicillinintermediate isolates varied, with >98% of isolates being susceptible to amoxicillin, amoxicillin-clavulanic acid (all formulations) and ceftriaxone, 60-70% to cefprozil and cefuroxime axetil, and <20% to cefaclor. b-Lactam susceptibility of penicillin-resistant isolates varied, with 83.3% of isolates being susceptible to amoxicillin-clavulanic acid (enhanced formulation), 70.9% to ceftriaxone, 60-62% to amoxicillin and amoxicillin-clavulanic acid (current formulation), and <2% to cefprozil, cefuroxime axetil and cefaclor. Levofloxacin (at 97.5%) and enhanced formulation amoxicillin/clavulanic acid (83.5%) showed the best activity against penicillin-resistant strains of S. pneumoniae (Table  4) . These data were further analyzed by country for cross-resistance between penicillin and the other classes of agents (Table 5) .
Since susceptibility to other b-lactam agents in each country largely followed the pattern of susceptibility by penicillin category shown above, these agents are not shown in Table 5 . The macrolides, clindamycin, and doxycycline were generally active (!84% susceptible) against penicillin-susceptible strains in most countries examined, except for France, Hong Kong, Italy, and Belgium. Trimethoprim/sulfamethoxazole activity was !83% susceptible in all countries except Australia (77.9%), Hong Kong (76.3%), Italy (60.1%), Mexico (71.8%) and Spain (79.4%). Resistance to all classes of agent generally increased with increasing penicillin resistance. France, with the lowest penicillin susceptibility (23% intermediate, 40% resistant) also had low macrolide susceptibility, even for penicillin- susceptible strains (66.4%), with decreasing susceptibility for penicillin-intermediate and -resistant strains (25.4% and 17.1%, respectively). Clindamycin, doxycycline, and trimethoprim/sulfamethoxazole also showed low susceptibility in French penicillin-resistant strains (19.7%, 40.2%, and 17.9% respectively). Hong Kong strains, with the highest penicillin resistance (56.9%), had low susceptibility to all of the agent classes (<10%), except for clindamycin, where 77.6% were susceptible.
In vitro activity against H. influenzae, based on the proportion of isolates susceptible (according to PK/PD breakpoints), from most active to least active, was: levofloxacin, ciprofloxacin, ceftriaxone, amoxicillin/clavulanic acid (enhanced formulation), cefixime, amoxicillin/clavulanic acid (current formulation), all with activity greater than 98%; amoxicillin, cefuroxime axetil, doxycycline, and cefprozil, ranging from 79%-22%; and cefaclor, azithromycin, erythromycin, and clarithromycin, at less than 3% (Table 2 ). While there was considerable variation in b-lactamase production and susceptibility to ampicillin, amoxicillin and trimethoprim/sulfamethoxazole between isolates from different countries (Figure 1) , there was little variation in susceptibility between countries for other agents. There was no association noted between b-lactamase production and resistance to trimethoprim/sulfamethoxazole in any country.
All M. catarrhalis isolates were susceptible (according to PK/PD breakpoints; there are no NCCLS breakpoints for this species) to amoxicillin/ clavulanic acid (both formulations), ciprofloxacin, and levofloxacin (Table 2) . b-Lactamase was produced by 93% of isolates. The in vitro activity of other agents against M. catarrhalis, based on proportion of isolates susceptible, from most active to least active, was cefixime, azithromycin, clarithromycin, erythromycin, ceftriaxone, and doxycycline, all with activity greater than 93%, and cefuroxime axetil, amoxicillin, cefprozil, and cefaclor, ranging from 52%-15%. There was little variation in susceptibility between countries for all agents.
No resistance to amoxicillin/clavulanic acid, amoxicillin, ampicillin, penicillin, ceftriaxone, cefprozil, cefuroxime axetil, and levofloxacin was seen in S. pyogenes. The in vitro activity of other agents against S. pyogenes, based on proportion of isolates susceptible (according to current NCCLS breakpoints and PK/PD breakpoints for agents without NCCLS breakpoints), from most to least active, was: cefixime, clindamycin, cefaclor, all over 90%, and erythromycin, clarithromycin, azithromycin, and doxycycline, which were all above 84% ( Table 2) .
The susceptibility of S. pyogenes from the USA, Canada, the UK, Australia, and the Netherlands to macrolides was 90% or greater (represented by erythromycin in Figure 2 ), while Italy had the lowest Comparative in vitro activity of a pharmacokinetically enhanced oral formulation 369 Susceptible PK/PD breakpoints used except for cefaclor, which was interpreted by PK/PD and NCCLS breakpoints, and cefixime, which was interpreted by PK/PD breakpoint. a Susceptibility at susceptible PK/PD / NCCLS breakpoints. b There were 15 levofloxacin-resistant isolates in this group, which were isolated in Belgium (1 isolate), France (1), Hong Kong (10), Mexico (1), Spain (1) , and the USA (1). 
Discussion
Several recent and ongoing surveillance studies have tracked the increasing prevalence of antibiotic resistance around the world. The prevalence of penicillin-resistant S. pneumoniae recently reported by country, ranged from less than 5% to nearly 70%. [27] [28] [29] [30] The prevalence of b-lactamase production by H. influenzae has been reported as low as 4% in Russia to a high of 30% in the USA. 29, 30 In this study, large differences in penicillin susceptibility in S. pneumoniae (from 37.3% susceptible in Hong Kong to 95.0% susceptible in the Netherlands) and b-lactamase production in H. influenzae (from 5% in Italy to 37% France) were found among the isolates recovered from the study sites in various countries around the world. These findings, not unlike those found in other studies, along with the necessity of empiric treatment of acute respiratory infections, underscores the importance of ongoing surveillance and reporting to keep clinicians aware of local trends.
Of the agents tested, levofloxacin remains the most active agent against S. pneumoniae, with 99% of all isolates and 97.5% of penicillin-resistant strains susceptible. Amoxicillin and amoxicillin/ clavulanic acid also remain very active against S. pneumoniae (93.5% susceptible for amoxicillin and current amoxicillin/clavulanic acid formulation and 97.3% for enhanced amoxicillin/clavulanic acid formulation), and are the most active oral b-lactams against penicillin-nonsusceptible strains (100% susceptible for penicillin-intermediate strains for amoxicillin and both amoxicillin/clavulanic acid formulations; for penicillin-resistant strains: 60.3% susceptible for amoxicillin and current amoxicillin/clavulanic acid formulation, and 83.5% for enhanced amoxicillin/clavulanic acid formulation). Amoxicillin/clavulanic acid continues to be very active against b-lactamase-producing H. influenzae strains (99.6% susceptible). The percentage of b-lactamase-negative ampicillinresistant H. influenzae strains remains extremely low (0.2%). The majority of M. catarrhalis worldwide are b-lactamase producers and amoxicillin/ clavulanic acid remains active with all MICs at 2 mg/mL. Although resistance to the macrolides and doxycycline is evident in several countries, most agents (including amoxicillin/clavulanic acid) continue to be very active against S. pyogenes. In other published studies, there has been a great deal of intercountry variation noted in erythromycin resistance in S. pyogenes, with prevalence in Europe and the USA ranging from 2-57%. [31] [32] [33] Italy is consistently one of the countries with the highest prevalence of erythromycin-resistant S. pyogenes, 34 while many other European countries and the USA report less than 10%.
Erythromycin resistance patterns in this study were consistent with published data: largely a problem in the European continent (especially Italy) and Hong Kong. 35 The United Kingdom and the Netherlands, at 100%, and Canada, at 98%, showed the highest prevalence of erythromycin susceptibility.
Overall, the most active oral agents against the common causative agents of community-acquired respiratory infections found in this study are the enhanced formulation of amoxicillin/clavulanic acid and levofloxacin. The parenteral agent, ceftriaxone, was also highly effective against these pathogens. The enhanced formulation of amoxicillin/clavulanic acid also showed excellent activity against strains resistant to other agents, and is a valuable addition to the range of oral agents suitable for the treatment of community-acquired respiratory infections.
